1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Pozen patents possibly prevent Par push for generic Treximet

 
• By Nancy Faigen

Pozen has filed a motion in a federal court to prevent generics maker Par Pharmaceutical from launching a generic version of its migraine combination treatment, Treximet (sumatriptan and naproxen sodium), in the US marketplace. Treximet is marketed in the US by GlaxoSmithKline.

Pozen has filed a motion in a federal court to prevent generics maker Par Pharmaceutical from launching a generic version of its migraine combination treatment, Treximet (sumatriptan and naproxen sodium), in the US marketplace. Treximet is marketed in the US by GlaxoSmithKline.

Pozen says that it believes Par, as first-filer, has the 180 days of market exclusivity for the product and could launch "at risk" after regulatory exclusivity for Treximet expires on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

More from Therapeutic Category

ASCO: Merck’s Zilo-V Shows Activity, But Numbers Still Small

 
• By Alaric DeArment

The drug boosted overall responses on top of the R-GemOx backbone, but the discussant pointed out that patients in waveLINE-003 were not very heavily pretreated.

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.